We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+7.43%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$994M
AUM Growth
-$12.8M
Cap. Flow
-$17.3M
Cap. Flow %
-1.74%
Top 10 Hldgs %
57.44%
Holding
72
New
15
Increased
6
Reduced
13
Closed
13

Top Buys

Rank Stock Value
1
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$106M
2
COLL icon
Collegium Pharmaceutical
COLL
+$26.7M
3
BPMC
Blueprint Medicines
BPMC
+$25.1M
4
ARDX icon
Ardelyx
ARDX
+$21.7M
5
MDCO
Medicines Co
MDCO
+$19.7M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$49.1M
2
ABUS icon
Arbutus Biopharma
ABUS
+$47.4M
3
DVAX
Dynavax Technologies
DVAX
+$39.9M
4
DYAX
DYAX CORPORATION
DYAX
+$39.9M
5
LRMR icon
Larimar Therapeutics
LRMR
+$29M

Sector Composition

Rank Sector Weight
1 Healthcare 75.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXMD icon
26
TherapeuticsMD
TXMD
$23.8M
$13.2M 1.33%
33,608
– –
AGRX
27
DELISTED
Agile Therapeutics
AGRX
$12.5M 1.26%
729
– –
ALPN
28
DELISTED
Alpine Immune Sciences Inc
ALPN
$11.5M 1.15%
+189,316
New +$11.3M
MCRB icon
29
Seres Therapeutics
MCRB
$45M
$10.2M 1.03%
+12,332
New +$10.8M
ARCT icon
30
Arcturus Therapeutics
ARCT
$165M
$9.98M 1%
+217,985
New +$9.99M
CNCE
31
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$9.95M 1%
668,406
+8,406
+1% +$128K
TENX icon
32
Tenax Therapeutics
TENX
$393M
$9.85M 0.99%
83
– –
SCMP
33
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$7.39M 0.74%
450,000
– –
ORKA
34
Oruka Therapeutics
ORKA
$5.31B
$6.53M 0.66%
+3,756
New +$4.94M
CYTO
35
DELISTED
Altamira Therapeutics Ltd
CYTO
$4.57M 0.46%
12
– –
AUPH icon
36
Aurinia Pharmaceuticals
AUPH
$1.95B
$3.45M 0.35%
1,142,676
-362,100
-24% -$1.34M
TRVN
37
DELISTED
Trevena, Inc.
TRVN
$3.31M 0.33%
845
-1,276
-60% -$5.39M
TTOO
38
DELISTED
T2 Biosystems, Inc
TTOO
$2.24M 0.23%
28
– –
FRTX
39
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.82M 0.18%
828
-1,402
-63% -$4.4M
VXRT
40
DELISTED
Vaxart
VXRT
$1.67M 0.17%
73,441
-54,182
-42% -$1.33M
MACK
41
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.44M 0.14%
14,794
– –
TSRO
42
DELISTED
TESARO, Inc.
TSRO
$1.38M 0.14%
23,500
– –
LUMO
43
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.33M 0.13%
3,333
– –
REGN icon
44
Regeneron Pharmaceuticals
REGN
$72.9B
$1.25M 0.13%
2,450
– –
PTCT icon
45
PTC Therapeutics
PTCT
$6.18B
$1.24M 0.12%
25,800
– –
ALKS icon
46
Alkermes
ALKS
$8.11B
$1.24M 0.12%
19,200
– –
NBIX icon
47
Neurocrine Biosciences
NBIX
$18.2B
$1.17M 0.12%
+24,400
New +$1.03M
CLVS
48
DELISTED
Clovis Oncology, Inc.
CLVS
$1.16M 0.12%
+13,200
New +$1.13M
ACAD icon
49
Acadia Pharmaceuticals
ACAD
$4.51B
$1.14M 0.12%
27,300
– –
INCY icon
50
Incyte
INCY
$25.8B
$1.11M 0.11%
+10,700
New +$1.11M
1
2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, RA Capital Management held 72 positions worth $994M, down 1.3% from $1.01B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

RA Capital Management's Q2 2015 filing shows 15 new, 6 increased, 13 reduced and 13 closed positions. Its largest new stake was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M. The largest sale was BioCryst Pharmaceuticals, an estimated $49.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 70% a quarter earlier.

  • RA Capital Management's largest Q2 2015 buy was Sio Gene Therapies Inc. Common Stock: 625,000 shares worth $102M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q2 2015, an estimated $16.4M increase.
  • RA Capital Management's biggest Q2 2015 reduction was BioCryst Pharmaceuticals, cutting an estimated $49.1M.
  • RA Capital Management fully exited Arbutus Biopharma in Q2 2015, selling an estimated $47.4M.
  • RA Capital Management's ten largest holdings make up 57% of its $994M portfolio in Q2 2015.
  • RA Capital Management opened 15 new positions and closed 13 in Q2 2015.
  • RA Capital Management's portfolio value fell 1.3% quarter-over-quarter to $994M.

Based on RA Capital Management's 13F filing for Q2 2015, filed 13 Aug 2015.